Anti-TNFRSF7/CD27 Antibody (Varlilumab) is a humanized agonistic monoclonal antibody targeting CD27 (TNFRSF7). This product specifically binds to the CD27 receptor on T cells, mimicking the costimulatory signal of the CD70 ligand and triggering the activation of the NF-kappaB signaling pathway. This action enhances the activation, proliferation, and cytokine secretion (such as IFN-gamma) of antigen-specific T cells. In preclinical models, the antibody induces potent anti-tumor immune responses; in clinical studies, combination with PD-1 inhibitors modulates the immune microenvironment and increases circulating chemokine levels.